Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists

被引：72

作者：

Antonelli, Alessandro ^{[1
]}

Ferrari, Silvia Martina ^{[1
]}

Fallahi, Poupak ^{[1
]}

Ghiri, Emiliano ^{[1
]}

Crescioli, Clara ^{[2
]}

Romagnani, Paola ^{[2
]}

Vitti, Paolo ^{[3
]}

Serio, Mario ^{[2
]}

Ferrannini, Ele ^{[1
]}

机构：

[1] Univ Pisa, Dept Internal Med, Sch Med, I-56100 Pisa, Italy

[2] Univ Florence, Dept Clin Pathophysiol, Endocrinol Unit, Florence, Italy

[3] Univ Pisa, Dept Endocrinol, I-56100 Pisa, Italy

来源：

CYTOKINE | 2010年 / 50卷 / 03期

关键词：

Interpheron-alpha; Interpheron-beta; CXCL9; CXCL10; Thyroid autoimmunity; AUTOIMMUNE THYROID-DISEASE; HUMAN ENDOTHELIAL-CELLS; CHRONIC HEPATITIS-C; GRAVES-DISEASE; CHEMOKINE CXCL10; SERUM-LEVELS; IFN-GAMMA; CLINICAL-APPLICATIONS; METHIMAZOLE-THERAPY; EXPRESSION;

D O I：

10.1016/j.cyto.2010.01.009

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

It has been hypothesized that interferon (IFN) alpha and beta cause autoimmune thyroid dysfunctions by changing the Th1/Th2 balance, but the mechanisms involved are not yet known. The aims of this study were: (a) to test the effect of IFNalpha, IFNbeta and IFNgamma on the secretion of the Th1 chemokines CXCL9 and CXCL10, in "primary cultures of human thyroid follicular cells" (TFC); (b) to assess the effect of PPARgamma activation on CXCL9 and CXCL10 secretion. In TFC, CXCL9 and CXCL10 were undetectable in the supernatant. IFNgamma, IFNalpha and IFNbeta, dose dependently induced CXCL9 and CXCL10 release. TNFalpha alone had no effect. The combination of each of the IFNs with TNFalpha had a significant synergistic effect on CXCL9 and CXCL10 secretion. Treatment of TFC with rosiglitazone dose dependently inhibited the IFNs-stimulated CXCL9 and CXCL10 release. Compared with IFNalpha and IFNbeta, IFNgamma was the most potent stimulus of CXCL9 and CXCL10 secretion. In conclusion, IFNalpha, IFNbeta, IFNgamma and TNFalpha (synergistically with IFNs) dose-dependently induce the release of CXCL9 and CXCL10 by TFC, suggesting that this process may be related, at least in part, to the appearance of thyroid dysfunction during IFNs therapy. Furthermore, PPARgamma activation partially inhibits this process. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：260 / 267

页数：8

共 45 条

[11] THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS [J].

BARON, S ;

TYRING, SK ;

FLEISCHMANN, WR ;

COPPENHAVER, DH ;

NIESEL, DW ;

KLIMPEL, GR ;

STANTON, GJ ;

HUGHES, TK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (10) :1375-1383

[12]

BHAKRI H, 1985, LANCET, V2, P457

[13] Type I Interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures [J].

Caraccio, N ;

Giannini, R ;

Cuccato, S ;

Faviana, P ;

Berti, P ;

Galleri, D ;

Dardano, A ;

Basolo, F ;

Ferrannini, E ;

Monzani, F .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) :1156-1162

[14] Hypothyroidism in transgenic mice expressing IFN-γ in the thyroid [J].

Caturegli, P ;

Hejazi, M ;

Suzuki, K ;

Dohan, O ;

Carrasco, N ;

Kohn, LD ;

Rose, NR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1719-1724

[15] Interferon alpha treatment and endocrine disease [J].

Chan, WB ;

Chow, CC ;

Cockram, CS .

JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2003, 96 (10) :481-485

[16]

Di Girolamo G, 2008, ARZNEIMITTELFORSCH, V58, P193, DOI 10.1055/s-0031-1296492

[17] A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon [J].

Fattovich, G ;

Giustina, G ;

Favarato, S ;

Ruol, A ;

Macarri, G ;

Orlandi, F ;

Iaquinto, G ;

Ambrosone, L ;

Francavilla, A ;

Pastore, G ;

Santantonio, MT ;

Romagno, D ;

Bolondi, L ;

Sofia, S ;

Marchesini, A ;

Pisi, E ;

Mazzella, G ;

Roda, E ;

Attaro, L ;

Chiodo, F ;

Mori, F ;

Verucchi, G ;

Lanzini, A ;

Salmi, A ;

Calvi, B ;

Bozzetti, F ;

Radaeli, E ;

Bernasconi, M ;

Pilleri, G ;

Bacca, D ;

Romano, G ;

Mastrapasqua, G ;

Cozzolongo, R ;

Cacopardo, B ;

Nunnari, A ;

Blasi, A ;

Sala, LO ;

Minoli, G ;

Sangiovanni, A ;

Spinzi, GC ;

Colombo, A ;

Camassa, M ;

Riva, D ;

Maggi, G ;

Boccia, S ;

Gualandi, G ;

Nucci, A ;

Pacini, F ;

Marino, N ;

Mazzotta, F .

JOURNAL OF HEPATOLOGY, 1996, 24 (01) :38-47

[18] Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+lymphocytes [J].

García-López, MA ;

Sancho, D ;

Sánchez-Madrid, F ;

Marazuela, M .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) :5008-5016

[19]

Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO

[20]

2-X

← 1 2 3 4 5 →